Tokai Pharmaceuticals Announces Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:44 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $2.00.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreBMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:43 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $1.70 (from $11.00) following the discontinuation of ARMOR3-SV.
Analyst Do Kim commented, "We are downgrading Tokai (TKAI) shares to Market Perform from Outperform, following the... More
Stifel Downgrades Tokai Pharmaceuticals (TKAI) to Hold
July 26, 2016 9:45 AM EDTStifel downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Hold after ARMOR3 stopped.
Analyst Thomas Shrader commented, "The ARMOR3 DMC has informed Tokai that the trial is unlikely to reach its rPFS endpoint (ruling of futility). Essentially no other data was... More
Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to Neutral
July 26, 2016 8:50 AM EDTJanney Montgomery Scott downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Neutral with a price target of $2.00 (from $12.00).
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreWells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 8:23 AM EDTWells Fargo downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... More